Welsch C W, Goodrich-Smith M, Brown C K, Mackie D, Johnson D
Oncology. 1982;39(2):88-92. doi: 10.1159/000225613.
Daily treatment of female Sprague-Dawley rats with CB-154 (prolactin suppressor) or Tamoxifen (estrogen antagonist) for 33 days before and after 7,12-dimethylbenzanthracene (DMBA) administration reduced (p less than 0.005) the incidence of mammary carcinomas by 58 and 49%, respectively. A combination of CB-154 and Tamoxifen further reduced (p less than 0.005) mammary carcinoma incidence by an additional 50-59%. Treatment with Tamoxifen for 66 days beginning 33 days after carcinogen treatment reduced (p less than 0.05) the incidence of mammary carcinomas by 65%; CB-154 treatment, during the same time period, did not significantly effect the final yield of mammary carcinomas. The combination of Tamoxifen and CB-154 was comparable to Tamoxifen alone in suppressing the incidence of mammary carcinomas in the latter study. These results demonstrate a substantial suppressive and synergistic effect of Tamoxifen and CB-154 in the initiating phases of mammary carcinogenesis while in the early promoting phases of this oncogenic process, short-term treatment with Tamoxifen was superior to CB-154 treatment; no synergism between these clinically important compounds was observed.
在给予7,12 - 二甲基苯并蒽（DMBA）之前及之后，用CB - 154（催乳素抑制剂）或他莫昔芬（雌激素拮抗剂）对雌性斯普拉格 - 道利大鼠进行为期33天的每日治疗，可使乳腺癌的发生率分别降低58%和49%（p < 0.005）。CB - 154与他莫昔芬联合使用可使乳腺癌发生率进一步降低50 - 59%（p < 0.005）。在致癌物处理33天后开始用他莫昔芬治疗66天，可使乳腺癌发生率降低65%（p < 0.05）；在同一时期用CB - 154治疗，对乳腺癌的最终产量没有显著影响。在后者的研究中，他莫昔芬与CB - 154联合使用在抑制乳腺癌发生率方面与单独使用他莫昔芬相当。这些结果表明，他莫昔芬和CB - 154在乳腺癌发生的起始阶段具有显著的抑制和协同作用，而在这个致癌过程的早期促进阶段，短期使用他莫昔芬优于CB - 154治疗；未观察到这些临床重要化合物之间的协同作用。
